[1] |
MARTIN S S,ABD T T,JONES S R,et al.2013 ACC/AHA cholesterol treatment guideline:what was done well and what could be done better[J]. J Am Coll Cardiol,2014,63(24):2674-2678.
|
[2] |
ARGUELLES W,LLABRE M M,PENEDO F J,et al.Relationship of change in traditional cardiometabolic risk factors to change in coronary artery calcification among individuals with detectable subclinical atherosclerosis:the multi-ethnic study of atherosclerosis[J]. Int J Cardiol,2014,174(1):51-56.
|
[3] |
ALLAIRE J,VORS C,COUTURE P,et al.LDL particle number and size and cardiovascular risk:anything new under the sun?[J]. Curr Opin Lipidol,2017,28(3):261-266.
|
[4] |
KANNEL W B,CASTELLI W P,MCNAMARA P M.Serum lipid fractions and risk of coronary heart disease. The Framingham study[J]. Minn Med,1969,52(8):1225-1230.
|
[5] |
SUPERKO H R,KING S 3rd. Lipid management to reduce cardiovascular risk:a new strategy is required[J]. Circulation,2008,117(4):560-568.
|
[6] |
SCHARNAGL H,NAUCK M,WIELAND H,et al.The Friedewald formula underestimates LDL cholesterol at low concentrations[J]. Clin Chem Lab Med,2001,39(5):426-431.
|
[7] |
SUPERKO H R.Advanced lipoprotein testing and subfractionation are clinically useful[J]. Circulation,2009,119(17):2383-2395.
|
[8] |
MORRIS P B,BALLANTYNE C M,BIRTCHER K K,et al.Review of clinical practice guidelines for the management of LDL-related risk[J]. J Am Coll Cardiol,2014,64(2):196-206.
|
[9] |
CROMWELL W C,OTVOS J D,KEYES M J,et al.LDL particle number and risk of future cardiovascular disease in the Framingham offspring study-implications for LDL management[J]. J Clin Lipidol,2007,1(6):583-592.
|
[10] |
VAKKILAINEN J,STEINER G,ANSQUER J C,et al.Relationships between low-density lipoprotein particle size,plasma lipoproteins,and progression of coronary artery disease:the Diabetes Atherosclerosis Intervention Study (DAIS)[J]. Circulation,2003,107(13):1733-1737.
|
[11] |
MCLEAN D S,RAVID S,BLAZING M,et al.Effect of statin dose on incidence of atrial fibrillation:data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials[J]. Am Heart J,2008,155(2):298-302.
|
[12] |
BARTER P J,BALLANTYNE C M,CARMENA R,et al.Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy:report of the thirty-person/ten-country panel[J]. J Intern Med,2006,259(3):247-258.
|
[13] |
AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices,COLE T G,CONTOIS J H,et al. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies:assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices[J]. Clin Chem,2013,59(5):752-770.
|
[14] |
SETH D,GARMO H,WIGERTZ A,et al.Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study[J]. Int J Mol Epidemiol Genet,2012,3(2):122-133.
|
[15] |
FREEDMAN D S,OTVOS J D,JEYARAJAH E J,et al.Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy:the Framingham Study[J]. Clin Chem,2004,50(7):1189-1200.
|
[16] |
QIN S Y,LIU J,JIANG H X,et al.Association between baseline lipoprotein (a) levels and restenosis after coronary stenting:meta-analysis of 9 cohort studies[J]. Atherosclerosis,2013,227(2):360-366.
|
[17] |
乔蕊,张捷. 脂蛋白(a)——血脂家族的重要一员[J]. 检验医学,2017,32(7):561-565.
|
[18] |
VON ECKARDSTEIN A,SCHULTE H,CULLEN P,et al.Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk[J]. J Am Coll Cardiol,2001,37(2):434-439.
|
[19] |
SULTAN S M,SCHUPF N,DOWLING M M,et al.Review of lipid and lipoprotein(a) abnormalities in childhood arterial ischemic stroke[J]. Int J Stroke,2014,9(1):79-87.
|
[20] |
Emerging Risk Factors Collaboration,ERQOU S,KAPTOGE S,et al. Lipoprotein(a) concentration and the risk of coronary heart disease,stroke,and nonvascular mortality[J]. JAMA,2009,302(4):412-423.
|
[21] |
MARCOVINA S M,ALBERS J J.Lipoprotein (a) measurements for clinical application[J]. J Lipid Res,2016,57(4):526-537.
|
[22] |
YEANG C,CLOPTON PC,TSIMIKAS S.Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects:implications for clinical practice interpretation of Lp(a)-mediated risk[J]. J Clin Lipidol,2016,10(6):1389-1396.
|
[23] |
SHARMA S,MERCHANT J,FLEMING S E.Lp(a)-cholesterol is associated with HDL-cholesterol in overweight and obese African American children and is not an independent risk factor for CVD[J]. Cardiovasc Diabetol,2012,11:10.
|
[24] |
PIRILLO A,NORATA G D,CATAPANO A L.High-density lipoprotein subfractions-what the clinicians need to know[J]. Cardiology,2013,124(2):116-125.
|
[25] |
CAMONT L,CHAPMAN M J,KONTUSH A.Biological activities of HDL subpopulations and their relevance to cardiovascular disease[J]. Trends Mol Med,2011,17(10):594-603.
|
[26] |
MASCARENHAS-MELO F,PALAVRA F,MARADO D,et al.Emergent biomarkers of residual cardiovascular risk in patients with low HDL-c and/or high triglycerides and average LDL-c concentrations:focus on HDL subpopulations,oxidized LDL,adiponectin,and uric acid[J]. Scientific World Journal,2013,2013:387849.
|
[27] |
BURILLO E,MARTÍN-FUENTES P,MATEO-GALLEGO R,et al. Omega-3 fatty acids and HDL. How do they work in the prevention of cardiovascular disease?[J]. Curr Vasc Pharmacol,2012,10(4):432-441.
|
[28] |
KULKARNI K R,MARCOVINA S M,KRAUSS R M,et al.Quantification of HDL2 and HDL3 cholesterol by the Vertical Auto Profile-Ⅱ (VAP-Ⅱ) methodology[J]. J Lipid Res,1997,38(11):2353-2364.
|
[29] |
MANGAT R,SU JW,LAMBERT J E,et al.Increased risk of cardiovascular disease in type 1 diabetes:arterial exposure to remnant lipoproteins leads to enhanced deposition of cholesterol and binding to glycated extracellular matrix proteoglycans[J]. Diabet Med,2011,28(1):61-72.
|
[30] |
中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志,2016,31(10):937-950.
|
[31] |
MAY H T,NELSON J R,KULKARNI K R,et al.A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography:the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL3+IDL])[J]. Lipids Health Dis,2013,12:55.
|